Successful infliximab therapy for oral Crohnʼs disease

Cardoso, Hélder; Nunes, Ana V. M.; Carneiro, Fátima; Veloso, Fernando Tavarela

doi:10.1097/01.mib.0000215096.51943.82

Cited by 17 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report describes the largest case series to date for patients with OFG+ ⁄ ) CD treated with anti-TNF-a therapy. Only a few cases and small case series (up to two patients) of the use of anti-TNF-a for OFG have previously been described, mostly reporting good shortterm benefit but with safety concerns raised (15)(16)(17)(18)(19)(20)(21)(22)(23). Seven per cent of patients referred to our clinic required anti-TNF-a therapy.…”

Section: Discussionmentioning

confidence: 99%

Experience with anti-TNF-α therapy for orofacial granulomatosis

Elliott¹,

Campbell

Escudier

et al. 2010

Journal of Oral Pathology &Amp; Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Experience with anti-TNF-α therapy for orofacial granulomatosis

Elliott¹,

Campbell

Escudier

et al. 2010

Journal of Oral Pathology &Amp; Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, dermatologists should consider the presence of an OFG as a possible early sign suggestive of another inflammatory intestinal disorder, such as CD. Several prior studies have suggested different treatment modalities for oral CD, ranging from the use of mouthwash with corticosteroids to intravenous infusions of an infliximab 9 . Consistent with the findings of previous reports 10 , a favourable outcome in our patient, using intralesional triamcinolone, is suggestive that this can be used as a treatment option for patients with CD that have oral lesions.…”

Section: Discussionmentioning

confidence: 99%

Orofacial Granulomatosis Associated with Crohn's Disease

Kim

Lee

2010

Ann Dermatol

View full text Add to dashboard Cite

“…30 Satisfactory results have been generally reported with the use of anti-TNFa agents at usual doses. 146,147 In fact, regarding the treatment of orofacial CD, infliximab has demonstrated remarkable efficacy in a series of patients 148,149 and also in some difficult-to-treat cases with pyostomatitis vegetans, 150 refractory mucosal aphthosis or fistulising oral CD. 151 In refractory oral CD, some authors suggested efficacy of thalidomide.…”

Section: Oral CDmentioning

confidence: 99%

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Κατσάνος

Torres

Roda

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Patients with inflammatory bowel diseases (IBD) may present with lesions in their oral cavity. Lesions may be associated with the disease itself representing an extraintestinal manifestation, with nutritional deficiencies or with complications from therapy. Aim To review and describe the spectrum of oral nonmalignant manifestations in patients with inflammatory bowel diseases [ulcerative colitis (UC), Crohn's disease (CD)] and to critically review all relevant data. Methods A literature search using the terms and variants of all nonmalignant oral manifestations of inflammatory bowel diseases (UC, CD) was performed in November 2014 within Pubmed, Embase and Scopus and restricted to human studies. Results Oral lesions in IBD can be divided into three categories: (i) lesions highly specific for IBD, (ii) lesions highly suspicious of IBD and (iii) nonspecific lesions. Oral lesions are more common in CD compared to UC, and more prevalent in children. In adult CD patients, the prevalence rate of oral lesions is higher in CD patients with proximal gastrointestinal tract and/or perianal involvement, and estimated to range between 20% and 50%. Oral lesions can also occur in UC, with aphthous ulcers being the most frequent type. Oral manifestations in paediatric UC may be present in up to one‐third of patients and are usually nonspecific. Conclusions Oral manifestations in IBD can be a diagnostic challenge. Treatment generally involves managing the underlying intestinal disease. In cases presenting with local disabling symptoms and impaired quality of life, local and systemic medical therapy must be considered and/or oral surgery may be required.

show abstract

Successful infliximab therapy for oral Crohnʼs disease

Cited by 17 publications

References 8 publications

Experience with anti-TNF-α therapy for orofacial granulomatosis

Experience with anti-TNF-α therapy for orofacial granulomatosis

Orofacial Granulomatosis Associated with Crohn's Disease

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Contact Info

Product

Resources

About